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Abstract
Background: Total cholesterol is a well-documented risk factor for coronary disease. Previous studies have shown
that high total cholesterol level is associated with better stroke outcomes, but the association of low total cholesterol
levels and ischemic stroke outcomes is rare. Therefore, we aimed to assess the association of low total cholesterol
levels and stroke outcomes among acute ischemic stroke patients in China.
Methods: This study recruited 6407 atherothrombotic infarction patients from Tianjin, China, between May 2005 and
September 2014. All patients were categorized into five groups according to TC level quintiles at admission. Differences
in subtypes, severity, risk factors, and outcomes at 3, 12, and 36 months after stroke were compared between these
groups.
Results: In total, 1256 (19.6 %) patients had low cholesterol levels, with a higher prevalence in men than in women
(23.7 % vs. 11.2 %, P < 0.001). Compared with higher cholesterol levels, the lowest cholesterol level quintile
(TC, <4.07 mmol/L) was associated with older age (64.7 years, P = 0.033), anterior circulation infarct (22.8 %),
atrial fibrillation (4.9 %), current smoking (41.1 %), and alcohol consumption (21.1 %) and lower frequencies
of hypertension (72.9 %), diabetes (30.7 %), and obesity (9.9 %). Dependency and recurrence rates were
significantly higher at 36 months in patients in the lowest TC level quintile than in those with higher cholesterol levels
(dependency rates, 51.2 % vs 45.2 %; P = 0.007 and recurrence rates, 46.3 % vs 37.3 %, P = 0.001). Moreover,
these differences remained after adjustment for age, sex, stroke severity, and Oxfordshire Community Stroke
Project classification (odds ratios [ORs] for dependency rate, 1.41; 95 % confidence interval [CI], 1.11, 1.79;
P = 0.005 and recurrence rate, 1.50; 95 % CI, 1.19, 1.89; P = 0.001). However, mortality rates after stroke were
not significantly different between the groups.
Conclusions: These findings suggest that statin treatment for patients with atherothrombotic infarction and
low cholesterol levels increase long-term dependency and recurrence rates, but do not increase mortality
rates. It is crucial to highlight the different impact of statin treatment on patients with atherothrombotic
infarction and lower cholesterol levels for secondary stroke prevention in China.
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Background
In 2010, stroke was the second most common cause of
death and the third most common cause of reduced
disability-adjusted life-years worldwide. Although age-
standardized rates of stroke mortality have decreased
worldwide in the past two decades, the absolute numbers
of annual stroke cases, stroke survivors, related deaths,
and the global burden of stroke disability-adjusted life-
years are high and are increasing [1, 2]. However, stroke
has recently become the leading cause of death in rural
areas, and the third most common cause of death in urban
areas in China [3]. High total cholesterol (TC) level is a
well-documented risk factor for coronary disease [4, 5],
but the association between total cholesterol levels and
stroke outcome is unclear. A large numbers of studies
indicated that high TC level was associated with better
stroke outcomes [6–8], but high TC level was associ-
ated with worse outcomes in other studies [9, 10]. Low
TC levels were associated with hemorrhagic, but not
ischemic stroke [11, 12]. The recent incidence of stroke
in China has increased dramatically, with economic
development [13]; however, a large-scale study of the
association between TC level and stroke outcomes is
rare in China, especially in patients with atherothrom-
botic infarction.
Therefore, we aimed to assess the association of low
TC level on admission and short-term and long-term




All consecutive patients with first-ever AIS who were
admitted to the Stroke Unit in Tianjin Huanhu Hospital
within 72 h of stroke onset between in May 2005 and
September 2014 were recruited to this study. A clinical
diagnosis of stroke was made according to the World
Health Organization criteria and confirmed by neuro-
imaging (computed tomography/magnetic resonance
imaging) [14]. Cases of transient ischemic attack were
excluded from this study, and all atherothrombotic
infarction patients classified according to the Trial of
Org 10,172 in Acute Stroke Treatment (TOAST) for
large artery atherothrombotic and small artery occlusion
(SAO) were analyzed in this study [15]. All patients were
treated using statin, and followed up for less than
3 months after AIS and TC level on admission was
available.
The study was approved by the ethics committee
for medical research at Tianjin Huanhu Hospital and
the Tianjin Health Bureau, and a written informed
consent for each participant was obtained during
recruitment.
Data collection and group
The detailed information on ischemic stroke subtype,
stroke severity, previous history of diseases, stroke risk
factors, laboratory examination results, and outcomes at
3, 12, and 36 months after stroke were collected using a
standardized questionnaire.
All patients were categorized into five groups ac-
cording to the TC level quintile at admission: group 1,
<4.07 mmol/L; group 2, 4.07–4.61 mmol/L; group 3,
4.62–5.15 mmol/L; group 4, 5.16–5.81 mmol/L; and group
5, >5.81 mmol/L.
Stroke subtypes
Stroke subtypes were defined as total anterior circulation
infarct (TACI), partial anterior circulation infarct (PACI),
posterior circulation infarct (POCI), and lacunar infarct
(LACI) according to Oxfordshire Community Stroke
Project (OCSP) classification criteria [16].
Neurological function deficit and stroke severity
Neurological function deficit was defined using the Na-
tional Institute of Health stroke scale (NIHSS), Barthel
index (BI) [17], and modified rankin scale (mRS) on ad-
mission [18]. Stroke severity was categorized into 3 groups
on the basis of NIHSS score: mild (NIHSS ≤7), moderate
(NIHSS between 8 to 16), and severe (NIHSS ≥ 17) [19].
Risk factors
Stroke risk factors included a medical history of hyper-
tension (defined as self-reported history of hypertension
or using antihypertension drugs), diabetes mellitus (DM,
defined as history of DM or using hypoglycemic medica-
tions at discharge), atrial fibrillation (AF, defined as history
of AF, confirmed by at least one electrocardiogram or the
presence of the arrhythmia during hospitalization); and
modifiable lifestyle factors, including current smoking sta-
tus, alcohol consumption, and obesity (body mass index
≥30 kg/m2).
Outcome definition
Stroke outcomes were described on the basis of mortality,
recurrence, and dependency rates at the short-term (at
3 months), medium-term (at 12 months), and long-term
(at 36 months) after stroke; outcomes were assessed using
face-to-face or telephone follow-up. Death was defined as
all-cause cumulative death at the corresponding time
points after stroke, and this information was collected
from patients’ family members by telephone follow-up.
Recurrence was defined as new-onset vascular events
(stroke, myocardial infarction, and venous thrombosis)
after 30 days of initial stroke in all survivors patients who
were followed up using face-to race interviews or tele-
phone calls. Dependency rate was defined as mRS > 2
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among all survivors followed up using face-to race inter-
view or telephone calls [20].
Follow-up periods
Follow-up was conducted according to a predetermined
procedure; the trained neurologists reexamined patients
in the outpatient department at 3, 12, 24, and 36 months
after stroke. All patients were followed-up by face-to-
face interview, but those patients reexamined in the
local hospital were followed-up by telephone.
Statistical analysis
Age is presented as mean (standard deviation), and
NIHSS, BI, and mRS are presented as median (inter-
quartile range). These continuous variables were com-
pared between the five TC groups using one-way analysis
of variance (ANOVA) or Kruskal-Wallis tests. At the
different time periods after stroke, categorical variables,
including stroke subtype, stroke severity, risk factors, and
outcomes, are presented as number (percentage), and
the trends were compared using Chi-square tests. Dif-
ferences in outcomes were compared between the five
groups using univariate and multivariate logistic regres-
sion models and are presented as unadjusted and ad-
justed (by sex, age, stroke severity, OCSP, and risk
factors [hypertension, diabetes, atrial fibrillation, artery
stenosis, obesity, current smoking, and alcohol con-
sumption]) odds ratios (OR), respectively, with 95 %
confidence intervals (CI). All statistical analyses were
performed using SPSS version 15.0 (SPSS Inc., Chicago,
IL), and two-tailed P values <0.05 were considered
statistically significant.
Fig. 1 Flow diagram of participants
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Results
Of the 7565 AIS patients recruited between May 2005
and September 2014, 392 patients with cardioembolic
stroke, 284 patients with other and undetermined causes
and 482 patients without a TC level recorded at admission
were excluded, resulting in 6407 patients with athero-
thrombotic infarction that were included. At 3 months,
155 patients were lost to follow-up, resulting in 6252
patients (response rate, 97.6 %). At 12 months, 269 pa-
tients were lost to follow-up, resulting in 5448 patients
(response rate, 95.3 %). At 36 months, 313 patients
were lost to follow-up, resulting in 3719 patients (response
rate, 92.2 %) (Fig. 1).
The lowest TC levels were present in 1256 (19.6 %) pa-
tients (1022 [23.7 %] men; 234 [11.2 %] women; P < 0.001;
Table 1). The mean age at stroke onset decreased with
increasing TC levels (P = 0.033). The prevalence of TACI
decreased, and the prevalence of POCI increased, with
increasing TC levels (P < 0.001). Moreover, the proportion
of patients with severe stroke increased with increasing
TC levels (P < 0.05); neurological function deficits at
admission were worse with increasing TC levels (P < 0.05).
The prevalence of AF, current smoking, and alcohol
consumption were significantly lower with higher TC
levels (all P < 0.05). In contrast, the prevalence of hyper-
tension, diabetes, and obesity increased with increasing
TC levels (all P < 0.001). The prevalence of artery stenosis
was not significantly different (Table 2).
There were no obvious differences in mortality and
dependency rates at all time points after AIS between
the TC level groups (Table 3). However, the recurrence
rate at 3 months was remarkably higher with higher TC
levels (group 1, 7.0 %; group 2, 7.4 %; group 3, 9.8 %;
group 4, 9.7 %; and group 5, 8.6 %; P = 0.038). The trend
in recurrence rates at 36 months after stroke was the
opposite to that at 3 months (group 1, 46.3 %; group 2,
41.0 %; group 3, 41.1 %; group 4, 37.7 %; and group 5,
37.3 %; P = 0.001).
In the univariate analysis, compared with the lowest
TC levels (group 1), mortality rates were lower at 3 and
12 months after stroke (by 32 and 29 %, respectively),
and the recurrence rate was lower at 36 months after
stroke (by 20 %) in those with TC levels of 4.62–
5.15 mmol/L (group 3). Compared with the lowest TC
level group (group 1), the dependency rate was 21 %
lower in group 2, 25 % lower in group 3, 20 % lower in
group 4, and 21 % lower in group 5 (Table 4).
In the multivariate analysis, the dependency rate was
significantly lower in the higher TC level groups com-
pared with group 1, by 21 % in group 2, 24 % in group
3, 22 % in group 4, and 29 % in group 5. The recurrence
rates in TC level groups 3 and 5 were significantly lower
Table 1 The clinical characteristics and risk factors in patients with acute ischemic stroke by TC levels
Characteristics Group 1 Group 2 Group 3 Group 4 Group 5 P
Numbers, n (%) 1256 (19.6) 1282 (20.0) 1283 (20.0) 1312 (20.5) 1274 (19.9) —
Gender, n (%) <0.001
Men 1022 (23.7) 959 (22.2) 907 (21.0) 794 (18.4) 637 (14.7)
Women 234 (11.2) 323 (15.5) 376 (18.0) 518 (24.8) 637 (30.5)
Age, year, means (SD) 64.69 (11.55) 64.10 (11.46) 63.59 (11.43) 63.36 (10.98) 63.94 (11.12) 0.033
OCSP classification, n (%): <0.001
TACI 63 (22.8) 59 (21.4) 54 (19.6) 46 (16.7) 54 (19.6)
PACI 720 (20.7) 688 (19.8) 704 (20.2) 716 (20.6) 651 (18.7)
LACI 82 (18.2) 118 (26.2) 85 (18.8) 90 (20.0) 76 (16.9)
POCI 391 (17.8) 417 (18.9) 440 (20.0) 460 (20.9) 493 (22.4)
Stroke severity: 0.001
Mild 849 (67.6) 907 (70.7) 886 (69.1) 889 (67.8) 803 (63.0)
Moderate 309 (24.6) 282 (22.0) 311 (24.2) 320 (24.4) 337 (26.5)
Severe 98 (7.8) 93 (7.3) 86 (6.7) 102 (7.8) 134 (10.5)
Neurological function deficit:
NIHSS 5 (7) 5 (6) 5 (7) 5 (7) 5 (7) 0.022
BI 60 (45) 60 (45) 60 (45) 60 (45) 60 (55) 0.006
mRS 3 (2) 3 (2) 3 (2) 3 (2) 3 (2) 0.006
TC total cholesterol, OCSP Oxfordshire Community Stroke Project, TACI total anterior circulation infarct, PACI partial anterior circulation infarct, POCI posterior
circulation infarct, LACI lacunar infarct, NIHSS National Institute of Health stroke scale, BI Barthel index, mRS modified rankin scale
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(by 20 and 27 %, respectively) than that in the lowest TC
group (group 1; Table 5).
Discussion
In this single-center study using a large stroke regis-
try in Tianjin, China, we assessed differences in age,
sex, stroke subtype, stroke severity, prevalence of risk
factors, and stroke outcomes between patients with
atherothrombotic infarction with and without low TC
levels. As a result, a low TC level was an independent
risk factor for outcomes in patients with atherothrombotic
infarction.
A high cholesterol level is a powerful risk factor for
coronary heart disease, but its role in stroke remains
controversial. Although observational studies have not
found a clear association between cholesterol levels and
stroke [21–25], associations between high serum TC levels
and an increased risk of ischemic stroke have been re-
ported [26, 27]. A study in Americans indicated a positive
association of TC levels with atherothrombotic infarction
[28]. Only one study conducted in Japan reported that
serum TC levels were positively associated with an in-
creased age-adjusted risk of atherothrombotic infarction
in Japanese women aged ≥40 years, but not in men [29].
A recent study showed that serum cholesterol
<160 mg/dL was a risk factor for hemorrhagic stroke
and increased the risk of death after hemorrhagic stroke,
but a reverse trend was found for ischemic stroke inci-
dence and death [11, 12]. Moreover, a study conducted in
Japan indicated that a higher TC level increased the risk of
cerebral infarction [11]. In a hospital-based study, low
serum TC levels were associated with increased risk of
severe stroke, TACI, and poor functional outcomes in
patients with ischemic stroke who had received pre-stroke
statin treatment, and the short-term and long-term mor-
tality rates were significantly higher in patients with low
cholesterol levels [30]. Another community-based cohort
study indicated that low cholesterol levels significantly
increased the risks of stroke and heart disease [31]. In
contrast with these previous findings, there was no signifi-
cant association between low cholesterol levels and mor-
tality after stroke in the present study.
A meta-analysis including 450,000 individuals from
45 observational cohorts suggested that there was no
association between TC level and the risk of fatal stroke
during an average follow-up of 16 years [32]. In another
meta-analysis of approximately 1 million individuals, a
clear association was found between the serum TC level
Table 2 The Prevalence of risk factors in patients with acute ischemic stroke by TC levels
Risk factors Total Group 1 Group 2 Group 3 Group 4 Group 5 P
Hypertension 4756 (74.2) 916 (72.9) 922 (71.9) 933 (72.7) 987 (75.2) 998 (78.3) <0.001
Diabetes 2090 (32.6) 386 (30.7) 370 (28.9) 418 (32.6) 411 (31.3) 505 (39.6) <0.001
Atrial fibrillation 231 (3.6) 62 (4.9) 46 (3.6) 41 (3.2) 46 (3.5) 36 (2.8) 0.010
Artery stenosis 1572 (24.5) 339 (27.0) 297 (23.2) 295 (23.0) 317 (24.2) 324 (25.4) 0.589
Obesity 795 (12.4) 124 (9.9) 141 (11.0) 130 (10.1) 192 (14.6) 208 (16.3) <0.001
Current smoking 2565 (40.0) 516 (41.1) 575 (44.9) 524 (40.8) 511 (38.9) 439 (34.5) <0.001
Alcohol consumption 1243 (19.4) 265 (21.1) 252 (19.7) 253 (19.7) 247 (18.8) 226 (17.7) 0.032
TC total cholesterol
Table 3 The outcome at 3, 12, and 36 months after stroke in acute ischemic stroke patients by TC levels
Outcomes Total Group 1 Group 2 Group 3 Group 4 Group 5 P
3 months:
Mortality 340 (5.4) 76 (6.2) 57 (4.6) 54 (4.3) 73 (5.7) 80 (6.5) 0.414
Dependency 602 (10.1) 124 (10.7) 125 (10.3) 108 (8.9) 111 (9.1) 134 (11.4) 0.962
Recurrence 207 (8.5) 81 (7.0) 90 (7.4) 118 (9.8) 118 (9.7) 100 (8.6) 0.038
12 months:
Mortality 454 (8.3) 91 (8.6) 87 (7.9) 68 (6.3) 94 (8.4) 114 (10.6) 0.080
Dependency 1218 (24.4) 258 (26.6) 239 (23.4) 234 (22.9) 250 (24.4) 237 (24.7) 0.538
Recurrence 1153 (22.7) 229 (23.3) 219 (20.9) 261 (25.4) 229 (22.0) 215 (21.8) 0.647
36 months:
Mortality 588 (15.8) 109 (15.5) 127 (16.1) 103 (13.6) 117 (15.9) 132 (18.2) 0.229
Dependency 1447 (46.2) 305 (51.2) 301 (45.4) 290 (44.1) 282 (45.5) 269 (45.2) 0.070
Recurrence 1359 (40.7) 294 (46.3) 291 (41.0) 289 (41.1) 249 (37.7) 236 (37.3) 0.001
TC total cholesterol, OR odds ratios, CI confidence intervals
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and the risk of fatal myocardial infarction, but again,
there was no obvious association with fatal stroke [25].
Consistent with the findings of previous studies, the
present study found that, compared with patients with
higher TC levels, patients with low TC levels were more
likely to be male; older; to have TACI or AF; be a
current smoker; and currently consume alcohol. Regard-
ing age, the TC level was associated with fatal ischemic
stroke in patients aged <70 years, but not in patients
aged >70 years in a previous study [25]. Moreover,
patients in the lowest TC level group were less likely to
have hypertension, diabetes, and obesity than patients in
the higher TC level groups.
Clinical trials using statins to reduce cholesterol levels
in patients with cardiovascular or cerebrovascular diseases
have shown significant reductions in the risk of stroke
[33–39] and that reduced cholesterol levels can reduce the
incidence of stroke in high-risk populations and in pa-
tients with a stroke or transient ischemic attack [25, 32].
Statin therapy has become the most important ad-
vancement in stroke prevention since aspirin and blood
pressure-lowering therapies were introduced. Statins not
only lower the overall risk of stroke but also reduce the
progression of carotid atherosclerosis; reduce inflamma-
tion and endothelial dysfunction; decrease platelet aggre-
gation to improve fibrinolysis; lower blood pressure; and
decrease the risk of thromboembolic complications in the
brain by reducing the incidence of myocardial infarction.
Statins might also have a neuroprotective effect [40–42].
However, clinicians should explore the effects of statin
Table 4 Un-adjusted OR (95 % CI) of TC levels in the outcomes at 3, 12, and 36 months after stroke in acute ischemic stroke
patients
Outcomes Group 1 Group 2 Group 3 Group 4 Group 5
3 months:
Mortality 1.00 0.72 (0.51, 1.03) 0.68 (0.47, 0.97)a 0.91 (0.66, 1.27) 1.04 (0.75, 1.44)
Dependency 1.00 0.96 (0.74, 1.24) 0.81 (0.62, 1.07) 0.83 (0.64, 1.09) 1.07 (0.83, 1.39)
Recurrence 1.00 0.87 (0.66, 1.14) 0.80 (0.60, 1.05) 0.79 (0.60, 1.05) 1.02 (0.78, 1.33)
12 months:
Mortality 1.00 0.91 (0.67, 1.23) 0.71 (0.51, 0.99)a 0.98 (0.72, 1.32) 1.27 (0.95, 1.70)
Dependency 1.00 0.84 (0.69, 1.03) 0.82 (0.67, 1.01) 0.89 (0.73, 1.09) 0.91 (0.74, 1.11)
Recurrence 1.00 0.90 (0.74, 1.09) 0.85 (0.70, 1.04) 0.93 (0.76, 1.13) 0.94 (0.77, 1.15)
36 months:
Mortality 1.00 1.05 (0.79, 1.38) 0.86 (0.64, 1.15) 1.03 (0.78, 1.37) 1.21 (0.92, 1.60)
Dependency 1.00 0.79 (0.64, 0.99)a 0.75 (0.60, 0.94)a 0.80 (0.64, 0.99)a 0.79 (0.63, 0.99)a
Recurrence 1.00 0.87 (0.70, 1.07) 0.80 (0.64, 0.99)a 0.83 (0.67, 1.03) 0.82 (0.66, 1.01)
TC total cholesterol, OR odds ratios, CI confidence intervals
a indicated P<0.05 refence as Group 1
Table 5 Adjusteda OR (95 % CI) of TC levels in the outcomes at 3, 12, and 36 months after stroke in acute ischemic stroke patients
Outcomes Group 1 Group 2 Group 3 Group 4 Group 5
3 months:
Mortality 1.00 0.77 (0.52, 1.13) 0.73 (0.49, 1.08) 1.08 (0.74, 1.55) 0.99 (0.68, 1.44)
Dependency 1.00 0.98 (0.75, 1.29) 0.84 (0.63, 1.10) 0.88 (0.67, 1.17) 1.04 (0.79, 1.37)
Recurrence 1.00 0.89 (0.68, 1.18) 0.82 (0.62, 1.09) 0.85 (0.64, 1.13) 1.02 (0.77, 1.35)
12 months:
Mortality 1.00 0.99 (0.70, 1.39) 0.74 (0.52, 1.07) 1.11 (0.79, 1.57) 1.22 (0.87, 1.71)
Dependency 1.00 0.86 (0.70, 1.06) 0.83 (0.68, 1.03) 0.92 (0.75, 1.13) 0.87 (0.71, 1.09)
Recurrence 1.00 0.91 (0.74, 1.11) 0.86 (0.70, 1.05) 0.95 (0.77, 1.16) 0.89 (0.72, 1.10)
36 months:
Mortality 1.00 1.15 (0.84, 1.58) 0.88 (0.63, 1.23) 1.12 (0.81, 1.56) 1.07 (0.77, 1.49)
Dependency 1.00 0.79 (0.63, 0.99)a 0.76 (0.60, 0.95)a 0.78 (0.62, 0.99)a 0.71 (0.56, 0.90)a
Recurrence 1.00 0.86 (0.70, 1.07) 0.80 (0.64, 0.99)a 0.81 (0.64, 1.01) 0.73 (0.58, 0.91)a
TC total cholesterol, OR odds ratios, CI confidence intervals
aAdjusted by sex, age, stroke severity, OCSP, risk factors (hypertension, diabetes, atrial fibrillation, artery stenosis, obesity, current smoking, and alcohol
consumption) as covariates
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treatment in patients with atherothrombotic infarction
and low TC levels.
Given the higher dependency and recurrence rates at
36 months after stroke in patients with the lowest TC
levels at admission in the present study, the benefits of
statin treatment for atherothrombotic infarction did not
appear to occur, supporting the role of low TC levels
as an independent risk factor for outcomes in these
patients. The mechanism explaining the association
between low TC levels and poorer stroke outcomes is
unknown. However, differences in race and social de-
velopment between Asian and Western populations might
partially explain the relationship.
There are several limitations in this study. First, all pa-
tients were from a local neurological hospital in
Tianjin, China, and may not represent all stroke pa-
tients in China. Second, the data on TC levels before
stroke was lacking; this may have affected the evalu-
ation of statin treatment.
Conclusion
In this large, hospital-based, prospective study using a
stroke registry from Tianjin, China, we assessed differ-
ences in stroke subtype, severity, risk factors, and out-
comes at 3, 12, and 36 months after stroke in patients
with atherothrombotic infarction based on different TC
levels. Men and older patients were more likely to have
low TC levels, and the frequencies of TACI, AF, current
smoking, and alcohol consumption were higher in pa-
tients with low TC levels than in patients with higher
TC levels. Furthermore, low TC levels were associated
with poor long-term outcomes, and a significant negative
relationship between cholesterol levels and dependency
and recurrence rates at 36 months after stroke onset were
observed. However, there was no significant difference in
mortality after stroke. Therefore, the TC level appears to
be a determinant of long-term outcomes in patients with
atherothrombotic infarction; statin treatment in the pa-
tients with lower TC levels increased the long-term risk of
dependency and recurrence, but not the risk of all-cause
death. Therefore, to improve secondary stroke prevention
in China, it is important to determine the different impact
of statin treatment in patients with atherothrombotic
infarction based on cholesterol levels.
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